Brind.
  1. UBS predicts high sales potential for Tyvaso, a drug whose market success is linked to NIH data and the broader treatment landscape.

United Therapeutics announced an expanded partnership with MannKind, covering a new development product.

4 reports, 3 independent Updated Aug 5
Gone quiet Reached 2 outlets in its first 24 hours
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

United Therapeutics announced an expanded partnership with MannKind, covering a new development product.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Partnership expansion and new product development for United Therapeutics.1 source
  2. Expanded collaboration between MannKind and United Therapeutics to develop a second inhaled therapy following FDA approval.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • dailypolitical.com
  • Simply Wall St.Why MannKind (MNKD) Is Up 11.7% After Expanding Technosphere Partnership With United Therapeutics On August 24, 2025, United Therapeutics announced an amendment to its license and collaboration agree
  • Simply Wall St.Should the Expanded Technosphere Partnership With MannKind Shape United Therapeutics’ (UTHR) Investment Outlook? On August 24, 2025, MannKind Corporation announced an amendment to its global license
  • GlobeNewswireMannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmo